Alex Philippidis is a Senior Business Editor at Inside Precision Medicine. He covers a diverse range of topics within medicine and healthcare, including healthcare technology, finance, and the evolving fields of cannabis and psychedelics. His work has been featured in notable publications such as Inside Precision Medicine and Genetic Engineering & Biotechnology News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Alex Philippidis mainly covers healthcare and pharmaceutical industry, focusing on investment analysis, private sector announcements, and press releases. He would likely be interested in receiving pitches related to breakthroughs in drug development, acquisitions within the biopharmaceutical industry, advancements in gene therapy as well as the application of AI in healthcare.
Given his interest in citing data and investment analysis, he might appreciate pitches that provide substantial data-driven insights into trends or companies within the healthcare and pharmaceutical sectors. Additionally, pitches featuring exclusive access to company executives for interviews or providing unique perspectives on M&A activities could also resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Alex Philippidis
Shares crater 80% after advisory committee sides with agency reviewers in recommending against approval of DMD cardiomyopathy cell therapy candidate, as August 22 PDUFA decision date looms
By: Alex Philippidis
The 4.5 year, up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked
By: Alex Philippidis
Thanks to its windfall of revenue from tirzepatide, the pharma giant reported second-quarter revenue and other results that beat analyst forecasts.
By: Alex Philippidis
Bristol Myers Squibb (BMS) has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch by producing multiple modalities of treatments—including small molecules, biologics, and antibody-drug conjugates (ADCs)—across disease areas.
For the first time, GEN examines the top regions and top states just below the 10 largest regions for life sciences activity, as the field looks beyond the East and West Coasts for growth
By: Alex Philippidis, Corinna Singleman, Julianna Lemieux
In this week's episode, editors discuss business news from BMS, Recursion and Genentech, and science updates on infectious diseases.
By: Alex Philippidis
A roundup of recent news based on interviews with executives from Fujifilm Biotechnologies, Lonza Group, MilliporeSigma, Samsung Biologics, and Thermo Fisher Scientific
By: Alex Philippidis
Intismeran autogene, an individualized neoantigen therapy, makes history on Wall Street as well as within the industry following its first positive Phase III data in a form of melanoma
By: Alex Philippidis
Industry group MassBio's report shows comebacks for VC, IPOs, and M&A activity—as well as funding challenges for startups and a three percent year-over-year decline in employment
By: Alex Philippidis
Aprea Therapeutics is accelerating enrollment in its ongoing Phase I trial of its targeted cancer therapy APR-1051, one of the precision oncology drug developer’s two lead programs, and expanding its indications under study after seeing early signs of clinical activity.
